Filing Analysis
Bone Biologics Corporation issued an 8-K to furnish a press release regarding corporate, scientific, and operational milestones achieved in 2026. The filing is intended for Regulation FD disclosure purposes.
📋 Key Facts
- The company released a press release on July 23, 2026, highlighting progress across various 2026 priorities.
- Milestones covered include corporate, scientific, and operational updates.
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Bone Biologics Corporation has announced the postponement of its 2026 annual meeting of stockholders from August 11, 2026, to September 28, 2026. The delay is due to the inclusion of an additional proposal in the upcoming Definitive Proxy Statement that requires more time for stockholder consideration.
🚩 Red Flags
- Postponement of annual meeting can sometimes signal internal governance issues or unexpected material developments requiring shareholder votes.
📋 Key Facts
- Original Annual Meeting Date: August 11, 2026
- New Annual Meeting Date: September 28, 2026, at 11:30 a.m. ET
- New Record Date for the meeting: August 6, 2026
- Deadline for stockholder submissions of director nominees or proposals: July 26, 2026
- Reason for postponement: Necessity to include an additional proposal in the proxy materials.
Bone Biologics Corp announced a private offering of pre-funded warrants and Series F/G warrants to an investor for approximately $2.7 million in net proceeds. The deal includes significant potential dilution through the issuance of over 6.3 million total shares upon exercise.
🚩 Red Flags
- Significant potential dilution: The offering involves a large number of warrants that could result in millions of new shares being issued.
- Pre-funded warrants with $0.001 exercise price act as immediate equity issuance, bypassing traditional capital raise mechanics.
- The company is required to seek shareholder approval for the issuance, indicating potential governance/structural complexity.
- High placement agent fees (8% aggregate) and additional warrant compensation.
📋 Key Facts
- Offering priced at $1.419 per Pre-Funded Warrant and accompanying Warrants.
- Pre-Funded Warrants allow purchase of common stock at an exercise price of $0.001 per share.
- Series F and Series G Warrants have an exercise price of $1.42 per share.
- Total shares involved: 2,112,677 Pre-Funded Warrants, 2,112,677 Series F Warrants, and 2,112,677 Series G Warrants.
- Net proceeds from the offering are approximately $2.7 million; potential additional gross proceeds of $6 million if warrants are fully exercised.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent with an 8% total fee (7% cash, 1% management).
- The company must seek shareholder approval for the issuance at its next annual or special meeting within 90 days.
Bone Biologics Corp has filed a prospectus supplement to sell up to $1,064,000 of common stock through an 'at the market' (ATM) offering program. The sales will be facilitated by H.C. Wainwright & Co., LLC as the sales agent under an existing agreement.
🚩 Red Flags
- Ongoing dilution risk from 'at the market' equity sales.
- Reliance on General Instruction I.B.6 indicates the company's public float is likely below $75 million.
- Frequent capital raising activity, having already utilized $1.7 million from a previous shelf registration.
📋 Key Facts
- Offering amount is up to $1,064,000 in common stock.
- Sales agent is H.C. Wainwright & Co., LLC.
- The offering is conducted under General Instruction I.B.6 of Form S-3 (the 'baby shelf' rule).
- Company previously sold approximately $1.7 million of common stock under a prior registration statement.
- The Shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-288290) effective as of September 2, 2025.
Bone Biologics Corporation issued an 8-K to furnish a press release summarizing its 2025 corporate, scientific, and operational milestones and providing a strategic outlook for 2026.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The company issued a press release on January 8, 2026, detailing 2025 achievements and 2026 strategic outlook.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Bone Biologics Corporation issued an 8-K to disclose a press release containing a CEO's Letter to Stockholders dated September 4, 2025.
🚩 Red Flags
- No specific financial distress or material event details are contained in this summary filing; however, CEO letters to stockholders can sometimes be used to manage sentiment during periods of volatility.
📋 Key Facts
- The filing is a disclosure under Item 7.01 (Regulation FD Disclosure).
- The primary content is a 'CEO’s Letter to Stockholders' issued via press release on September 4, 2025.
- The company is listed on the Nasdaq Capital Market under ticker BBLG.
Bone Biologics Corp completed a public offering of common stock and various warrant series on June 30, 2025. The offering included pre-funded warrants and multiple tiers of warrants (Series D and E) to institutional investors.
🚩 Red Flags
- Significant dilution: The issuance of over 1.2 million warrants and pre-funded warrants represents a massive increase in potential share count relative to existing shares (1.6M).
- Complex warrant structure: Multiple tiers of warrants (Series D, E, Pre-Funded) with different expiration dates and exercise prices.
- High cost of capital: 8% aggregate fee to the placement agent plus reimbursement for legal/out-of-pocket expenses.
📋 Key Facts
- Offered 793,750 shares of Common Stock at $4.00 per share plus Series D and E warrants.
- Offered 456,250 Pre-Funded Warrants at $3.999 per warrant (exercise price of $0.001).
- Net proceeds from the offering are approximately $4.3 million.
- Potential additional gross proceeds from warrants if fully exercised: ~$10 million.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent with an 8% total fee (7% cash, 1% management).
- The company had 1,605,260 shares of Common Stock outstanding after the closing.
Bone Biologics Corporation announced on June 26, 2025, that it has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
🚩 Red Flags
- History of non-compliance with Nasdaq minimum bid price requirements (Rule 5550(a)(2)).
📋 Key Facts
- Received a letter from Nasdaq Listing Qualifications Department on June 25, 2025.
- Confirmed compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- The company previously faced potential delisting due to falling below the $1.00 threshold.
Bone Biologics Corporation has announced a 1-for-6 reverse stock split effective June 10, 2025. The action aims to consolidate common shares while maintaining the existing trading symbol 'BBLG'.
🚩 Red Flags
- Reverse stock split is a common defensive measure often used by micro-cap companies to avoid Nasdaq delisting due to minimum bid price requirements.
- The filing mentions risks associated with being an 'undercapitalized developing company'.
📋 Key Facts
- Reverse stock split ratio of 1-for-6 shares.
- Effective date: 12:01 a.m. ET on June 10, 2025.
- Common stock will continue to trade under symbol 'BBLG' on Nasdaq Capital Market.
- Warrants (BBLGW) will undergo proportionate adjustments to exercise price and share count.
- Fractional shares will be rounded up to the nearest whole share.
Bone Biologics Corporation held an annual meeting of stockholders on May 30, 2025, where shareholders approved several key items, most notably a reverse stock split in a range between 1-for-2.5 and 1-for-10.
🚩 Red Flags
- Approval of a reverse stock split (often used to maintain Nasdaq listing compliance or combat low share prices).
- Significant increase in equity incentive plan pool (30M additional shares), which may lead to future dilution.
- Low quorum/participation: Only 1,626,829 shares were present/represented out of 3,271,042 entitled to vote (~50% participation).
📋 Key Facts
- Stockholders approved a reverse stock split within a range of 1-for-2.5 to 1-for-10 at the Board's discretion.
- The 2015 Equity Incentive Plan was amended to increase reserved shares by 30,000,000, bringing total available shares to 30,354,077.
- Four directors (Bruce Stroever, Siddhesh Angle, Robert Gagnon, and Philip Meikle) were elected to the Board.
- Weinberg & Company, P.A. was ratified as the independent registered public accounting firm for fiscal year 2025.
- The company's total shares entitled to vote at the meeting were 3,271,042.
Bone Biologics Corporation received a notice from Nasdaq indicating it is in violation of the minimum bid price requirement (Rule 5550(a)(2)). The company has a 180-day compliance period ending October 6, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Planned reverse stock split to artificially inflate share price
- Failure to maintain minimum bid price requirement for 30 consecutive business days
📋 Key Facts
- Received notice from Nasdaq on April 7, 2025, regarding failure to maintain $1.00 minimum bid price.
- Compliance period expires on October 6, 2025.
- To regain compliance, the company must achieve a closing bid price of at least $1.00 for 10 consecutive business days within the period.
- The Board intends to seek stockholder approval for a reverse stock split at the upcoming annual meeting to address the deficiency.
Bone Biologics Corporation announced the date for its 2025 Annual Meeting of Stockholders, scheduled for May 30, 2025. The filing also establishes new deadlines for shareholder proposals and director nominations due to the meeting being held more than 30 days before the anniversary of the previous annual meeting.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for May 30, 2025.
- A Definitive Proxy Statement (Schedule 14A) will be filed with the SEC to provide detailed information and proposals.
- Due dates for shareholder proposals or director nominations have been moved up to April 11, 2025.
- The company is listed on the Nasdaq Capital Market under ticker BBLG.
Bone Biologics Corporation has filed a prospectus supplement to increase the maximum aggregate dollar amount of shares eligible for sale under its existing At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Continuous use of ATM (At The Market) offerings often indicates a need for immediate liquidity to fund operations.
- Small dollar amounts in the supplement suggest micro-cap scale, but frequent updates can lead to significant dilution for existing shareholders.
📋 Key Facts
- The Company updated the maximum amount of shares eligible for sale under the Sales Agreement dated September 27, 2024.
- The new maximum aggregate dollar amount is $832,009.
- The company previously sold approximately $846,288 of Common Stock via this agreement.
- The offering is being conducted through H.C. Wainwright & Co., LLC.
Bone Biologics Corporation announced the appointment of Phillip Meikle to its Board of Directors on October 16, 2024. Mr. Meikle is a veteran healthcare executive with significant experience in the orthopedic and spine industry.
📋 Key Facts
- Phillip Meikle appointed to the Board of Directors effective October 16, 2024.
- Meikle has over 32 years of experience in the orthopedic and spine industry.
- Founder and CEO of Biosystems of New England, Inc., which was sold to Stryker in 2019.
- Has served as a consultant for Stryker for the past five years.
Bone Biologics Corporation announced the immediate resignation of Director Don Hankey on October 1, 2024. The company stated that his departure was not due to any disagreement regarding the company's operations, policies, or practices.
📋 Key Facts
- Don Hankey resigned from the Board of Directors effective October 1, 2024.
- The resignation is characterized as not being due to any disagreements with the Company.
- Filing date: October 4, 2024.
Bone Biologics Corporation entered into an At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell common stock from time to time. This allows the company to raise capital through various trading methods on the Nasdaq Capital Market.
🚩 Red Flags
- Small offering size ($1.14M) suggests limited immediate liquidity runway and potential for significant dilution to existing shareholders.
- ATM offerings are often used by micro-cap companies facing cash constraints to fund operations.
📋 Key Facts
- Entered into ATM Offering Agreement with H.C. Wainwright & Co., LLC on September 27, 2024.
- Aggregate market value of shares eligible for sale is $1,143,121 (based on Form S-3 General Instruction I.B.6).
- Wainwright will receive a 3.0% commission on aggregate gross proceeds.
- The company will reimburse Wainwright for expenses up to $100,000 plus specific due diligence session fees.
- Offering terminates upon the sale of $1,143,121 in shares or mutual termination.
Bone Biologics Corporation held its Annual Meeting of Stockholders on September 17, 2024. The meeting resulted in the election of four directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on September 17, 2024.
- Four director nominees elected: Don Hankey, Bruce Stroever, Siddhesh Angle, and Robert Gagnon.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay).
- Weinberg & Company, P.A. was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Bone Biologics Corporation entered into inducement agreements to facilitate the exercise of existing warrants, resulting in approximately $2.1 million in gross proceeds. The transaction involves issuing new warrants with lower strike prices and includes significant placement agent fees.
🚩 Red Flags
- Significant dilution: Issuance of new warrants with lower strike prices ($2.00 vs original $2.43) dilutes existing shareholders.
- Cash crunch indicator: The company is seeking a relatively small amount ($2.1M) to fund clinical trials and working capital, suggesting limited runway.
- High cost of capital: Combined placement agent fees (8% total cash + warrants) represent a significant percentage of the gross proceeds.
📋 Key Facts
- Gross proceeds from the Inducement Transaction are expected to be approximately $2.1 million.
- Existing warrant holders will pay an exercise price of $2.43 per share.
- In exchange, the company is issuing new 5-year and 18-month warrants with a lower strike price of $2.00 per share.
- H.C. Wainwright & Co., LLC is serving as the exclusive placement agent.
- Placement agent fees include an 7.0% cash fee, a 1.0% management fee, and warrants to purchase up to 46,875 shares of common stock at $3.35 per share.
Bone Biologics Corporation announced the commencement of its pilot clinical study for the NB1 bone graft device, noting that the first two patients have been treated in spine fusion procedures. This is a regulatory/clinical milestone disclosure under Item 7.01.
📋 Key Facts
- First two patients have been treated in a pilot clinical study of the NB1 bone graft device.
- The clinical application being tested is spine fusion.
- The announcement was made via press release on June 20, 2024.
Bone Biologics Corporation announced amendments to the employment agreements for its CEO, Jeffrey Frelick, and CFO, Deina Walsh. The updates primarily focus on transaction bonuses contingent upon a potential acquisition of the company.
🚩 Red Flags
- Incentive structures (transaction bonuses) suggest management may be incentivized toward a sale rather than long-term organic growth.
📋 Key Facts
- Effective Jan 1, 2024, an amended/restated agreement was entered into with CEO Jeffrey Frelick.
- CEO compensation includes $300,000 annual base salary and a target bonus of 50% based on KPIs.
- CEO is eligible for a transaction bonus of 1% to 2% of total transaction value in the event of an acquisition.
- CFO Deina Walsh's agreement was amended effective March 11, 2024.
- CFO is eligible for a transaction bonus of 0.5% to 1% of total transaction value in the event of an acquisition.
Bone Biologics Corporation completed a public offering of common stock and warrants on March 6, 2024, raising approximately $1.5 million in net proceeds. The offering included pre-funded warrants that allow investors to acquire shares at a nominal cost of $0.001 per share.
🚩 Red Flags
- Significant dilution potential from pre-funded warrants (662,251 shares) and standard warrants.
- Pre-funded warrants at $0.001 exercise price effectively act as immediate equity issuance upon conversion.
- High placement agent compensation including significant expense reimbursements ($100k+).
- Ownership limitations in warrants (4.99% or 9.99%) suggest structured financing to avoid certain regulatory thresholds.
📋 Key Facts
- Priced public offering: 119,000 common shares and warrants at $2.56 per share/warrant combo.
- Pre-funded warrants issued: 662,251 units to purchase common stock at $2.559 per unit.
- Net proceeds from offering: Approximately $1.5 million after fees.
- Warrants exercise price: $2.43 per share; term of five years.
- Pre-funded warrants exercise price: $0.001 per share (immediately exercisable).
- Placement Agent: H.C. Wainwright & Co., LLC received 7% cash fee and 1% management fee, plus reimbursement for expenses up to $100,000.
- Post-closing share count: 879,176 shares of Common Stock outstanding.
Bone Biologics Corporation issued an 8-K to announce a press release regarding clinical progress in its NB1 program. The filing does not contain material financial changes or structural corporate events.
📋 Key Facts
- The company reported progress with its NB1 clinical program via a press release dated March 1, 2024.
- The filing is categorized under Item 8.01 (Other Events).
- No financial statements or material agreements were disclosed in the body of this specific 8-K.
Bone Biologics Corporation has entered into a Settlement Agreement and Mutual General Release to resolve claims of breach of contract and tortious interference involving former officers/directors. The settlement requires the Company to pay $750,000 in cash.
🚩 Red Flags
- Significant cash outflow ($750,000) for legal settlement in a micro-cap context.
- Legal disputes involving breach of contract and tortious interference with former management/directors.
- Indemnification obligations related to former officer Stephen LaNeve.
📋 Key Facts
- Settlement effective date: January 9, 2024.
- The agreement settles claims filed in the U.S. District Court for the District of Massachusetts.
- Plaintiffs include Drs. Bessie (Chia) Soo and Kang (Eric) Ting; Defendant includes Stephen LaNeve.
- Company must pay $750,000 in cash within 20 business days of execution.
- Insurance carrier is expected to cover $400,000 less certain retention amounts.
Bone Biologics Corporation announced a change in its Board of Directors, involving the appointment of Robert E. Gagnon and the resignation of Erick Lucera.
📋 Key Facts
- Robert E. Gagnon appointed to the Board of Directors on January 8, 2024.
- Erick Lucera resigned from the Board effective December 27, 2023.
- Mr. Gagnon will serve as chair of the Audit Committee and a member of the Compensation and Nominating/Corporate Governance Committees.
- Robert E. Gagnon brings significant finance experience, including roles at Verastem Oncology, Harvard Bioscience, Clean Harbors, and Biogen Idec.
Bone Biologics Corporation announced on January 10, 2024, that it has successfully regained compliance with the Nasdaq Capital Market listing standards. This follows a period of non-compliance that likely threatened the company's continued trading status.
🚩 Red Flags
- Previous non-compliance with Nasdaq listing standards indicates historical regulatory/governance issues.
📋 Key Facts
- Company regained compliance with Nasdaq Capital Market listing standards as of January 10, 2024.
- The announcement was made via press release (Exhibit 99.1).
- The filing is reported under Item 8.01 (Other Events).
Bone Biologics Corporation announced the resignation of director Erick Lucera, effective upon the appointment of a successor. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Erick Lucera resigned as a director on December 27, 2023.
- The resignation is effective upon the appointment of a new director.
- The company explicitly stated there were no disagreements with Mr. Lucera regarding operations, policies, or practices.